Literature DB >> 14988385

Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid.

Shinji Sakamoto1, Masahiro Yokoyama, Xianghua Zhang, Kulkarni Prakash, Kaori Nagao, Takashi Hatanaka, Robert H Getzenberg, Yoshiyuki Kakehi.   

Abstract

Lysophosphatidic acid (LPA) is an endogenous lipid growth factor that is thought to play important roles in cell proliferation and antiapoptosis and therefore may have roles in the development and progression of benign prostatic hyperplasia (BPH). CYR61 (CCN1), on the other hand, is a growth factor-inducible immediate early gene that functions in cell proliferation, differentiation, and extracellular matrix synthesis. Here we show the close relationship between LPA-induced expression of CYR61 and prostate enlargement. CYR61 mRNA and protein were dramatically up-regulated by 18:1 LPA (oleoyl-LPA) within 1 and 2 h, respectively, in both stromal and epithelial prostatic cells. G protein-coupled receptors, i.e. Edg-2, Edg-4, and Edg-7, for LPA were also expressed in both stromal and epithelial prostatic cells. Furthermore, on DNA microarray analysis for normal and BPH patients, CYR61 was found to be related to the development and progression of BPH, regardless of symptoms. Although CYR61 mRNA was synthesized in hyperplastic epithelial cells, in many cases of BPH, CYR61 protein was detected in both the epithelial and stromal regions of BPH patient tissues. The functional contribution of CYR61 to prostatic cell growth was demonstrated by recombinant CYR61 protein and anti-CYR61 neutralizing antibodies, which inhibited CYR61-dependent cell spreading and significantly diminished cell proliferation, respectively. In conclusion, these data support the hypothesis that LPAs induce the expression of CYR61 by activating G proteincoupled receptors and that CYR61 acts as a secreted autocrine and/or paracrine mediator in stromal and epithelial hyperplasia, demonstrating the potential importance of this signaling mechanism in the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988385      PMCID: PMC3477642          DOI: 10.1210/en.2003-1350

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  41 in total

Review 1.  Physiological responses to lysophosphatidic acid and related glycero-phospholipids.

Authors:  G Tigyi
Journal:  Prostaglandins Other Lipid Mediat       Date:  2001-04       Impact factor: 3.072

2.  Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines.

Authors:  C Guo; L M Luttrell; D T Price
Journal:  J Urol       Date:  2000-03       Impact factor: 7.450

Review 3.  Lysophosphatidic acid, a multifunctional phospholipid messenger.

Authors:  W H Moolenaar
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

Review 4.  Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator.

Authors:  K Jalink; P L Hordijk; W H Moolenaar
Journal:  Biochim Biophys Acta       Date:  1994-12-30

5.  Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.

Authors:  D Xie; C W Miller; J O'Kelly; K Nakachi; A Sakashita; J W Said; J Gornbein; H P Koeffler
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

6.  Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factor-induced signal transduction.

Authors:  U R Pendurthi; K E Allen; M Ezban; L V Rao
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

Review 7.  Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate.

Authors:  E J Goetzl; S An
Journal:  FASEB J       Date:  1998-12       Impact factor: 5.191

8.  Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells.

Authors:  Yuhuan Xie; Terra C Gibbs; Yurii V Mukhin; Kathryn E Meier
Journal:  J Biol Chem       Date:  2002-06-25       Impact factor: 5.157

Review 9.  Benign prostatic hyperplasia. Current pharmacological treatment.

Authors:  M Jønler; M Riehmann; R C Bruskewitz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 10.  Lysophospholipid mediators of immunity and neoplasia.

Authors:  Mei Chuan Huang; Markus Graeler; Geetha Shankar; Juliet Spencer; Edward J Goetzl
Journal:  Biochim Biophys Acta       Date:  2002-05-23
View more
  13 in total

1.  Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.

Authors:  C Rory Goodwin; Bachchu Lal; Xin Zhou; Sandra Ho; Shuli Xia; Alexandra Taeger; Jamie Murray; John Laterra
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

2.  Extracellular matrix associated protein CYR61 is linked to prostate cancer development.

Authors:  Katherine B D'Antonio; Antoun Toubaji; Roula Albadine; Alison M Mondul; Elizabeth A Platz; George J Netto; Robert H Getzenberg
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

Review 3.  High-fat diet, obesity and prostate disease: the ATX-LPA axis?

Authors:  Prakash Kulkarni; Robert H Getzenberg
Journal:  Nat Clin Pract Urol       Date:  2009-02-10

4.  Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.

Authors:  Naoki Terada; Takumi Shiraishi; Yu Zeng; Steven M Mooney; David B Yeater; Leslie A Mangold; Alan W Partin; Prakash Kulkarni; Robert H Getzenberg
Journal:  Prostate       Date:  2011-10-24       Impact factor: 4.104

5.  Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.

Authors:  Ze Liu; Mandi M Hopkins; Zhihong Zhang; Chrystal B Quisenberry; Louise C Fix; Brianna M Galvan; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2014-12-09       Impact factor: 4.030

Review 6.  G protein-coupled receptors go extracellular: RhoA integrates the integrins.

Authors:  Colin T Walsh; Dwayne Stupack; Joan Heller Brown
Journal:  Mol Interv       Date:  2008-08

7.  The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Cell Biol       Date:  2010-06-06       Impact factor: 28.824

Review 8.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

9.  Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61.

Authors:  Colin T Walsh; Julie Radeff-Huang; Rosalia Matteo; Albert Hsiao; Shankar Subramaniam; Dwayne Stupack; Joan Heller Brown
Journal:  FASEB J       Date:  2008-08-07       Impact factor: 5.191

10.  Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Authors:  Mandi M Murph; Wenbin Liu; Shuangxing Yu; Yiling Lu; Hassan Hall; Bryan T Hennessy; John Lahad; Marci Schaner; Aslaug Helland; Gunnar Kristensen; Anne-Lise Børresen-Dale; Gordon B Mills
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.